RxDoctor Payments Data

John Tsou, MD

Internal Medicine · Hudson, NYNPI 1750348983

Payments from drug & device makers

$1,428in general payments, 2019–2025

Across 81 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$198
  • Bayer$189
  • Johnson & Johnson$133
  • Otsuka America Pharmaceutical, Inc.$103
  • Lilly USA, LLC$96
  • AstraZeneca$88
  • plus $621 from 18 others

What the payments were for

  • Food & beverage$1,428100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,428 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$93,552
Medicare patients
248
Services billed
1,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban318$122,496
OzempicSemaglutide84$92,856
RexultiBrexpiprazole104$72,715
JanuviaSitagliptin Phosphate56$68,338
TradjentaLinagliptin34$32,520
TrulicityDulaglutide25$30,562
FarxigaDapagliflozin Propanediol30$29,070
MounjaroTirzepatide29$28,326
JardianceEmpagliflozin16$23,418
Lantus SolostarInsulin Glargine,hum.Rec.Anlog172$23,079
OxycontinOxycodone Hcl14$21,124
XareltoRivaroxaban39$20,753
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog35$16,988
Novolog FlexpenInsulin Aspart63$16,402
Humalog Kwikpen U-100Insulin Lispro65$15,669

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$122,496318 claims
Novo NordiskOzempic, Novolog$198$100,407110 claims
Otsuka America Pharmaceutical, Inc.Rexulti$103$72,715104 claims
MerckJanuvia$60$68,33856 claims
Lilly USA, LLCTrulicity, Mounjaro$96$58,88854 claims
AstraZenecaFarxiga$88$29,07030 claims
Johnson & JohnsonXarelto$133$20,75339 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$7,772556 claims
Sanofi-aventis U.S. LLCLantus$19$2,73015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Hudson

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →